Loading...
Loading...
ZVRA| Name | Value |
|---|---|
| Revenues | 3.7M |
| Cost of Revenue | 2.3M |
| Gross Profit | 1.4M |
| Operating Expense | 28.7M |
| Operating I/L | -27.3M |
| Other Income/Expense | -5.9M |
| Interest Income | 0.0M |
| Pretax | -33.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -33.2M |
Zevra Therapeutics, Inc. is a rare disease company in the United States that specializes in discovering and developing proprietary prodrugs to treat serious medical conditions. The company's focus is on utilizing its Ligand Activated Therapy technology to create improved prodrug versions of FDA-approved drugs and develop prodrug versions of existing compounds for new disease indications. Zevra's product pipeline includes KP1077, a prodrug candidate for idiopathic hypersomnia and narcolepsy, and KP879 for stimulant use disorder. Additionally, the company has FDA-approved products such as AZSTARYS for attention deficit hyperactivity disorder and APADAZ for pain management.
